Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Neutralizing Amine Use in Hospital Steam Boilers

Regulations and Compliance Hospitals use steam boilers to meet a variety of needs including domestic hot water, space heating, food preparation, sterilization, and humidification. The use of water treatment compounds called “neutralizing amines” can be a source of confusion, especially where plant steam is used for humidification and sterilization. Recently updated standards provide clear guidance…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Regulations and Compliance

Hospitals use steam boilers to meet a variety of needs including domestic hot water, space heating, food preparation, sterilization, and humidification. The use of water treatment compounds called “neutralizing amines” can be a source of confusion, especially where plant steam is used for humidification and sterilization. Recently updated standards provide clear guidance on neutralizing amine use in hospital steam boiler systems.

What are Neutralizing Amines?

Without proper treatment, steam condensate will become acidic and cause severe corrosion damage to the condensate return system. Neutralizing amines are volatile compounds that control corrosion by neutralizing the corrosive carbonic acid that forms in the condensate due to the thermal decomposition of the natural alkalinity in the boiler makeup water. Neutralizing amines are essential for effective corrosion control, but must be properly applied and monitored to meet regulatory guidelines.

Key Standards and Regulations

ASHRAE1/ASHE2 Standard 170-2013 (Ventilation of Health Care Facilities) specifies that the additives used in steam systems serving humidifiers in healthcare facilities must comply with U.S. FDA regulations (21 CFR 173.310). These FDA regulations define the boiler water additives (including neutralizing amines) that are approved for use in boilers where the steam comes in direct contact with food.

AAMI3 ST79:2017 (Comprehensive Guide to Steam Sterilization and Sterility Assurance in Health Care Facilities) provides recommended practices for steam quality, steam purity, and monitoring for effective steam sterilization. AAMI ST79 also dictates that only FDA approved boiler additives be used and provides recommendations for boiler chemical application and monitoring.

Where condensate system corrosion cannot be controlled without exceeding FDA regulated maximum amine levels, a dealkalizer or reverse osmosis system may be necessary to reduce the makeup water alkalinity.

Add Neutralizing Amines to Feedwater

AAMI ST79 requires that boiler additives including amines always be injected into the boiler feedwater, and specifically states that amines should NOT be injected into the steam header or steam lines.

Adding the amine product to the feedwater tank or deaerator helps ensure good dilution in a large volume of water prior to steam generation. When the feedwater eventually turns to steam, the amine concentration will be much more consistent regardless of the steaming rate, condensate return, which boiler is online, where the steam flows, etc. Since amine dosage requirements are a direct function of how much natural alkalinity enters the boiler system via the makeup water, it is recommended they be fed in direct proportion to boiler makeup water usage.

Any facility that requires FDA/USDA approval should feed amines to the feedwater to ensure consistent distribution. Other industries that use steam for humidification such as laboratories, textiles, semiconductor, electronics, etc. would fall under the same guidelines. Although adding amine to the feedwater instead of the steam will result in some loss due to venting and blowdown, the amount is usually minor.

Monitoring Neutralizing Amine Levels

To confirm compliance with FDA/USDA regulations, a condensed steam sample should be periodically taken for laboratory analysis to determine neutralizing amine levels. The steps include:

  1. Collect steam sample directly from the steam header or a steam line before any steam traps or vented receivers. Condensate samples will not provide representative test results.
  2. Use a sample cooler or cooling coil to completely condense the steam sample (no flashing). Flush sample to drain for 15 minutes prior to collection.
  3. Fill a clean plastic sample bottle to the top, allowing a slight overflow. Cap immediately, taking care to assure there is no head space of air above the liquid.
  4. Label sample bottle identifying the specific amines to be tested. Promptly ship to testing laboratory.

Conclusion

Chem-Aqua has the capabilities, experience, and expertise to help you protect your building water systems and stay in compliance with key regulations. For additional information on this topic, email Chem-Aqua at info@chemaqua.com to request a copy of the Technical Bulletin TB1-030 “Neutralizing Amine Use in Hospital Steam Boilers.”

Chem-Aqua is a global leader in custom-designed programs for boilercooling, and process water systems. Since 1919, our success has been built upon our Total System Approach, providing solutions for water treatment problems and improving water system efficiencies. Learn more about how we can help protect your systems at our website.

Footnotes:

  1. American Society of Heating, Refrigerating and Air-Conditioning Engineers;
  2. American Society for Healthcare Engineering;
  3. Association of the Advancement for Medical Instruments

Read more at chemaqua.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512